Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (37805) 37805
Publication (5436) 5436
Book Review (665) 665
Book / eBook (329) 329
Book Chapter (268) 268
Newsletter (149) 149
Newspaper Article (80) 80
Conference Proceeding (72) 72
Dissertation (36) 36
Magazine Article (13) 13
Data Set (6) 6
Transcript (4) 4
Paper (2) 2
Reference (2) 2
Government Document (1) 1
Presentation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (22963) 22963
animals (21318) 21318
humans (20296) 20296
mice (11663) 11663
male (10486) 10486
female (9371) 9371
immunology (8533) 8533
rats (4826) 4826
research (4605) 4605
pharmacology & pharmacy (4534) 4534
inflammation (4492) 4492
expression (4461) 4461
neurosciences (4314) 4314
cell biology (4254) 4254
analysis (3932) 3932
oncology (3840) 3840
receptor (3742) 3742
proteins (3729) 3729
cancer (3726) 3726
mice, inbred c57bl (3721) 3721
health aspects (3509) 3509
article (3459) 3459
rodents (3459) 3459
research article (3398) 3398
adult (3300) 3300
medicine (3286) 3286
cytokines (3275) 3275
middle aged (3256) 3256
disease models, animal (3109) 3109
gene expression (3103) 3103
signal transduction (3058) 3058
receptors (2995) 2995
activation (2970) 2970
multidisciplinary sciences (2938) 2938
physiological aspects (2886) 2886
care and treatment (2846) 2846
in-vivo (2833) 2833
dendritic cells (2804) 2804
biochemistry & molecular biology (2784) 2784
lymphocytes (2565) 2565
apoptosis (2523) 2523
medicine, research & experimental (2519) 2519
t cells (2470) 2470
immunotherapy (2426) 2426
science (2404) 2404
cells, cultured (2340) 2340
medicine & public health (2256) 2256
aged (2248) 2248
mice, knockout (2218) 2218
immune system (2185) 2185
antigens (2173) 2173
physiology (2123) 2123
biomedicine (2007) 2007
cells (1971) 1971
mice, inbred balb c (1947) 1947
flow cytometry (1896) 1896
genetic aspects (1889) 1889
antibodies (1846) 1846
tumors (1830) 1830
hematology (1821) 1821
immune response (1767) 1767
ligands (1748) 1748
rats, sprague-dawley (1748) 1748
macrophages (1730) 1730
biology (1719) 1719
endocrinology & metabolism (1717) 1717
treatment outcome (1704) 1704
cell line, tumor (1673) 1673
medical research (1661) 1661
brain (1656) 1656
disease (1647) 1647
dose-response relationship, drug (1626) 1626
kinases (1622) 1622
review (1613) 1613
t-cells (1610) 1610
lymphocytes t (1606) 1606
studies (1595) 1595
therapy (1584) 1584
drug therapy (1579) 1579
in-vitro (1520) 1520
monoclonal antibodies (1510) 1510
t cell receptors (1466) 1466
rheumatology (1428) 1428
immunoglobulins (1417) 1417
toll-like receptors (1415) 1415
antibodies, monoclonal - therapeutic use (1388) 1388
t-lymphocytes - immunology (1386) 1386
animal models (1377) 1377
risk factors (1373) 1373
time factors (1370) 1370
immunity (1365) 1365
internal medicine (1315) 1315
tumor-necrosis-factor (1311) 1311
gene-expression (1308) 1308
development and progression (1302) 1302
rheumatoid-arthritis (1287) 1287
monoclonal-antibody (1283) 1283
abridged index medicus (1261) 1261
pharmacology/toxicology (1248) 1248
biochemistry (1234) 1234
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (255) 255
UofT at Mississauga - Stacks (15) 15
Collection Dvlpm't (Acquisitions) - Closed Orders (11) 11
UTL at Downsview - May be requested (11) 11
Online Resources - Online (7) 7
Collection Dvlpm't (Acquisitions) - Vendor file (6) 6
UofT at Scarborough - Stacks (6) 6
Engineering & Comp. Sci. - Stacks (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Gerstein Science - Periodical Stacks (1) 1
Pontifical Inst. Mediaeval Studies - Library use only (1) 1
Providence Healthcare - Reference (1) 1
Providence Healthcare - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
St. Michael's Hospital - Stacks (1) 1
Toronto East General Hospital - Stacks (1) 1
Trinity College (John W Graham) - Stacks (1) 1
Trinity College (John W Graham) - Storage (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (38414) 38414
French (37) 37
Spanish (28) 28
Japanese (24) 24
Russian (18) 18
Chinese (12) 12
German (12) 12
Italian (3) 3
Korean (3) 3
Polish (3) 3
Turkish (3) 3
Arabic (2) 2
Dutch (2) 2
Portuguese (2) 2
Swedish (2) 2
Hungarian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Mixed Metastatic Lung Cancer Lesions in Bone Are Inhibited by Noggin Overexpression and Rank:Fc Administration
by Feeley, Brian T and Liu, Nancy Q and Conduah, Augustine H and Krenek, Lucie and Roth, Kevin and Dougall, William C and Huard, Johnny and Dubinett, Steve and Lieberman, Jay R
Journal of Bone and Mineral Research, ISSN 0884-0431, 10/2006, Volume 21, Issue 10, pp. 1571 - 1580
Lung cancer metastases to bone produce a primarily mixed osteolytic/osteoblastic lesion. The purpose of this study was to determine if blockade of both... 
RANK:Fc protein | RANK ligand | RANK | bone metastasis | osteoclastogenesis | noggin | Noggin | Osteoclastogenesis | Bone metastasis | Bone Morphogenetic Proteins - antagonists & inhibitors | Neoplasm Transplantation | Bone Neoplasms - therapy | Humans | Lung Neoplasms - metabolism | Recombinant Fusion Proteins - therapeutic use | Bone Neoplasms - secondary | Lung Neoplasms - pathology | Male | Bone Neoplasms - pathology | Tibia - pathology | Carcinoma, Non-Small-Cell Lung - pathology | Cytokines - metabolism | Carcinoma, Non-Small-Cell Lung - metabolism | Tibia - diagnostic imaging | Mice, SCID | Osteoclasts - metabolism | Osteolysis - metabolism | Radiography | Carrier Proteins - genetics | Animals | Carrier Proteins - metabolism | Cell Line, Tumor | Mice | Osteoclasts - drug effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank : Fc administration
by Feeley, BT and Liu, NQ and Conduah, AH and Krenek, L and Roth, K and Dougall, WC and Huard, J and Dubinett, S and Lieberman, JR
JOURNAL OF BONE AND MINERAL RESEARCH, ISSN 0884-0431, 10/2006, Volume 21, Issue 10, pp. 1571 - 1580
Lung cancer metastases to bone produce a primarily mixed osteolytic/osteoblastic lesion. The purpose of this study was to determine if blockade of both... 
RANK ligand | bone metastasis | OSTEOLYTIC LESIONS | noggin | BMP SIGNALING INHIBITION | RANK | BREAST-CANCER | OSTEOCLAST DEPLETION | PROSTATE-CANCER | IN-VIVO | ENDOCRINOLOGY & METABOLISM | RECEPTOR ACTIVATOR | RANK : Fc protein | CYSTINE KNOT PROTEIN | osteoclastogenesis | KAPPA-B LIGAND | MORPHOGENETIC PROTEIN-2
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
by Powell, Jerry S and Josephson, Neil C and Quon, Doris and Ragni, Margaret V and Cheng, Gregory and Li, Ella and Jiang, Haiyan and Li, Lian and Dumont, Jennifer A and Goyal, Jaya and Zhang, Xin and Sommer, Jurg and McCue, Justin and Barbetti, Margaret and Luk, Alvin and Pierce, Glenn F
Blood, ISSN 0006-4971, 03/2012, Volume 119, Issue 13, pp. 3031 - 3037
Current factor VIII (FVIII) products display a half-life (t(1/2)) of similar to 8-12 hours, requiring frequent intravenous injections for prophylaxis and... 
PROPHYLACTIC TREATMENT | IMPACT | THERAPY | ORTHOPEDIC STATUS | PROGRESS | TAILORED PROPHYLAXIS | OUTCOMES | HEMATOLOGY | VON-WILLEBRAND-FACTOR | CHILDREN | Recombinant Fusion Proteins - adverse effects | Factor VIII - pharmacokinetics | Humans | Middle Aged | Receptors, Fc - metabolism | Recombinant Fusion Proteins - therapeutic use | Half-Life | Male | Metabolic Clearance Rate | Immunoglobulin Fc Fragments - administration & dosage | Receptors, Fc - therapeutic use | Dose-Response Relationship, Drug | Young Adult | Time Factors | Adult | Factor VIII - adverse effects | Immunoglobulin Fc Fragments - therapeutic use | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Factor VIII - therapeutic use | von Willebrand Factor - analysis | Infusion Pumps | Hemophilia A - blood | Hemophilia A - metabolism | Receptors, Fc - administration & dosage | Recombinant Fusion Proteins - pharmacokinetics | Factor VIII - administration & dosage | Hemophilia A - drug therapy | Clinical Trials and Observations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Intravaginal administration of Fc-fused IL7 suppresses the cervicovaginal tumor by recruiting HPV DNA vaccine-induced CD8 T cells
by Choi, Young Woo and Kang, Moon Cheol and Seo, Yong Bok and Namkoong, Hong and Park, Yunji and Choi, Dong-Hoon and Suh, You Suk and Lee, Seung-Woo and Sung, Young Chul and Jin, Hyun-Tak
Clinical Cancer Research, ISSN 1078-0432, 12/2016, Volume 22, Issue 23, pp. 5898 - 5908
Purpose: The induction of tissue-localized virus-specific CD8 T-cell response is essential for the development of an effective therapeutic vaccine against... 
GAMMA | RESPONSES | CLINICAL-TRIAL | ONCOLOGY | FEMALE GENITAL-TRACT | HELPER-CELLS | RECEPTOR | HUMAN-PAPILLOMAVIRUS | INTRAEPITHELIAL NEOPLASIA | LESIONS | IL-7 | Dendritic Cells - immunology | Mice, Inbred C57BL | Vaccines, DNA - immunology | Uterine Cervical Neoplasms - immunology | Administration, Intravaginal | Alphapapillomavirus - immunology | Interleukin-7 - administration & dosage | Cancer Vaccines - immunology | Immunity, Cellular - immunology | Animals | Interleukin-7 - immunology | Vaccination - methods | Papillomavirus Infections - immunology | Uterine Cervical Neoplasms - virology | Female | Papillomavirus Vaccines - immunology | Mice | CD8-Positive T-Lymphocytes - immunology | Cytokines - immunology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Half-life extended biotherapeutics
by Kontermann, Roland E
Expert Opinion on Biological Therapy, ISSN 1471-2598, 07/2016, Volume 16, Issue 7, pp. 903 - 915
Introduction: Many of the biotherapeutics approved or under development suffer from a short half-life necessitating frequent applications in order to maintain... 
polymer | half-life extension | fusion protein | PEGylation | Albumin | FcRn | glycosylation | Fc region | MEDICINE, RESEARCH & EXPERIMENTAL | SINGLE-CHAIN DIABODY | LONG-ACTING ERYTHROPOIETIN | FACTOR VIIA | GONADOTROPIN-BETA-SUBUNIT | ALBUMIN-BINDING DOMAIN | PH-DEPENDENT BINDING | NEONATAL FC-RECEPTOR | GLUCAGON-LIKE PEPTIDE-1 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | CARBOXYL-TERMINAL PEPTIDE | Biological Therapy - methods | Biological Therapy - trends | Albumins - metabolism | Immunoglobulin Fc Fragments - metabolism | Humans | Receptors, Fc - metabolism | Half-Life | Albumins - administration & dosage | Glycosylation - drug effects | Immunoglobulin Fc Fragments - administration & dosage | Histocompatibility Antigens Class I - metabolism | Animals | Receptors, Fc - administration & dosage | Histocompatibility Antigens Class I - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII‐Fc Fusion Protein
by Groomes, Charles L and Gianferante, David M and Crouch, Gary D and Parekh, Dina S and Scott, David W and Lieuw, Kenneth
Pediatric Blood & Cancer, ISSN 1545-5009, 05/2016, Volume 63, Issue 5, pp. 922 - 924
The development of inhibitors toward factor VIII (FVIII) is a common and serious complication of hemophilia A (HA) therapy. Patients with hemophilia who... 
recombinant factor VIII‐Fc fusion protein | hemophilia A | eloctate | factor VIII inhibitors | immune tolerance induction | Eloctate | Immune tolerance induction | Recombinant factor VIII-Fc fusion protein | Hemophilia A | Factor VIII inhibitors | recombinant factor VIII-Fc fusion protein | HEMOPHILIA-A PATIENTS | THERAPY | ONCOLOGY | PEDIATRICS | HEMATOLOGY | IMMUNOLOGICAL-TOLERANCE | Recombinant Fusion Proteins - immunology | Factor VIII - immunology | Hemophilia A - immunology | Humans | Factor VIII - genetics | Infant | Male | Receptors, Fc - immunology | Receptors, Fc - administration & dosage | Factor VIII - administration & dosage | Factor VIII - antagonists & inhibitors | Recombinant Fusion Proteins - genetics | Receptors, Fc - genetics | Blood Coagulation Factor Inhibitors - immunology | Hemophilia A - drug therapy | Desensitization, Immunologic | Recombinant Fusion Proteins - administration & dosage | Immune Tolerance - drug effects | Blood coagulation factor VIII | Hemophilia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A Single Intravenous sTNFR-Fc Administration at the Time of Reperfusion Limits Infarct Size—Implications in Reperfusion Strategies in Man
by Toufektsian, Marie-Claire and Robbez-Masson, Vanessa and Sanou, Drissa and Jouan, Marie-Gabrielle and Ormezzano, Olivier and de Leiris, Joël and Boucher, François
Cardiovascular Drugs and Therapy, ISSN 0920-3206, 12/2008, Volume 22, Issue 6, pp. 437 - 442
Reperfusion of the ischemic myocardium is associated with increased inflammatory processes that can exert deleterious effects and therefore contribute to... 
Remodelling | Medicine & Public Health | TNF-α | Transient ischemia | Cardiology | sTNFR-Fc | Cardiac dysfunction | ISCHEMIA/REPERFUSION INJURY | CARDIAC & CARDIOVASCULAR SYSTEMS | TNF-alpha | HEART-FAILURE | RATS | ISCHEMIA | NECROSIS-FACTOR-ALPHA | MESSENGER-RNA | ACUTE MYOCARDIAL-INFARCTION | PHARMACOLOGY & PHARMACY | EXPRESSION | Recombinant Proteins - therapeutic use | Staining and Labeling - methods | Tumor Necrosis Factor-alpha - metabolism | Rats, Wistar | Humans | Echocardiography - methods | Male | Receptors, Tumor Necrosis Factor - therapeutic use | Myocardial Reperfusion Injury - pathology | Etanercept | Time Factors | Myocardial Infarction - pathology | Immunoglobulin G - pharmacology | Myocardial Reperfusion Injury - drug therapy | Disease Models, Animal | Myocardial Infarction - diagnosis | Data Interpretation, Statistical | Immunoglobulin G - therapeutic use | Rats | Receptors, Tumor Necrosis Factor - administration & dosage | Recombinant Proteins - pharmacology | Forecasting | Immunoglobulin G - administration & dosage | Recombinant Proteins - administration & dosage | Ventricular Dysfunction, Left - physiopathology | Animals | Evans Blue | Myocardial Infarction - drug therapy | Ventricular Dysfunction, Left - drug therapy | Injections, Intravenous - methods | Hemodynamics - drug effects | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Ventricular Dysfunction, Left | Injections, Intravenous | Echocardiography | Immunoglobulin G | Recombinant Proteins | Tumor Necrosis Factor-alpha | Tissues and Organs | Life Sciences | Human health and pathology | Myocardial Infarction | Receptors, Tumor Necrosis Factor | Staining and Labeling | Myocardial Reperfusion Injury | Hemodynamics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Human NgR-Fc Decoy Protein via Lumbar Intrathecal Bolus Administration Enhances Recovery from Rat Spinal Cord Contusion
by Wang, Xingxing and Yigitkanli, Kazim and Kim, Chang-Yeon and Sekine-Konno, Tomoko and Wirak, Dana and Frieden, Eric and Bhargava, Ajay and Maynard, George and Cafferty, William B.J and Strittmatter, Stephen M
Journal of Neurotrauma, ISSN 0897-7151, 12/2014, Volume 31, Issue 24, pp. 1955 - 1966
Axonal growth and neurological recovery after traumatic spinal cord injury (SCI) is limited by the presence of inhibitory proteins in myelin, several of which... 
Original Articles | myelin | contusion | AXONAL REGENERATION | OUTGROWTH INHIBITOR | ANTIBODY | Nogo | IDENTIFICATION | NEUROSCIENCES | translational science | MYELIN-ASSOCIATED GLYCOPROTEIN | CLINICAL NEUROLOGY | STROKE | traumatic spinal cord injury | NEURITE OUTGROWTH | GROWTH | Nogo receptor | pharmacokinetics | SOLUBLE NOGO-66 RECEPTOR | CENTRAL-NERVOUS-SYSTEM | CRITICAL CARE MEDICINE | Injections, Spinal | Spinal Cord Injuries - drug therapy | Recovery of Function - drug effects | Humans | Rats | Rats, Sprague-Dawley | Recombinant Proteins - administration & dosage | Animals | Receptors, Fc - administration & dosage | Myelin Proteins - administration & dosage | Female | Nogo Receptor 1 | Receptors, Cell Surface - administration & dosage | Neuroprotective Agents - administration & dosage | GPI-Linked Proteins - administration & dosage | Disease Models, Animal | Neurology | Care and treatment | Spinal cord injuries | Diagnosis | Analysis | Proteins | Pharmacology | Neurons | Rodents | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences
by Acqua, William F. Dall and Woods, Robert M and Ward, E. Sally and Palaszynski, Susan R and Patel, Nita K and Brewah, Yambasu A and Wu, Herren and Kiener, Peter A and Langermann, Solomon
The Journal of Immunology, ISSN 0022-1767, 11/2002, Volume 169, Issue 9, pp. 5171 - 5180
Many biological functions, including control of the homeostasis and maternofetal transfer of serum gamma-globulins, are mediated by the MHC class I-related... 
SITE | COMPLEX | MUTAGENESIS | CRYSTAL-STRUCTURE | I-RELATED RECEPTOR | MHC | MICE | LIGAND | IMMUNOLOGY | IMMUNOGLOBULIN-G | BINDING | Surface Plasmon Resonance | Receptors, IgG - administration & dosage | Animals, Newborn - genetics | Injections, Intravenous | Immunoglobulin G - blood | Humans | Receptors, Fc - metabolism | Histocompatibility Antigens Class I | Peptide Library | Receptors, IgG - metabolism | Organ Specificity - immunology | Bacteriophage M13 - genetics | Organ Specificity - genetics | Receptors, IgG - genetics | Infant, Newborn | Receptors, IgG - blood | Mutagenesis, Site-Directed | Binding Sites, Antibody - genetics | Injections, Intramuscular | Bacteriophage M13 - immunology | Immunoglobulin G - administration & dosage | Precipitin Tests | Animals | Immunoglobulin G - genetics | Receptors, Fc - administration & dosage | Receptors, Fc - genetics | Mice | Mice, Inbred BALB C | Animals, Newborn - immunology | Receptors, Fc - blood | Hydrogen-Ion Concentration | Immunoglobulin G - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
by Kuter, David J, Prof and Bussel, James B, MD and Lyons, Roger M, MD and Pullarkat, Vinod, MD and Gernsheimer, Terry B, MD and Senecal, Francis M, MD and Aledort, Louis M, MD and George, James N, MD and Kessler, Craig M, MD and Sanz, Miguel A, MD and Liebman, Howard A, MD and Slovick, Frank T, MD and de Wolf, J Th M, MD and Bourgeois, Emmanuelle, MD and Guthrie, Troy H, MD and Newland, Adrian, MA and Wasser, Jeffrey S, MD and Hamburg, Solomon I, MD and Grande, Carlos, MD and Lefrère, François, MD and Lichtin, Alan Eli, MD and Tarantino, Michael D, MD and Terebelo, Howard R, DO and Viallard, Jean-François, MD and Cuevas, Francis J, MD and Go, Ronald S, MD and Henry, David H, MD and Redner, Robert L, MD and Rice, Lawrence, MD and Schipperus, Martin R, MD and Guo, D Matthew, PhD and Nichol, Janet L, MS
Lancet, The, ISSN 0140-6736, 02/2008, Volume 371, Issue 9610, pp. 395 - 403
Summary Background Chronic immune thrombocytopenic purpura (ITP) is characterised by accelerated platelet destruction and decreased platelet production.... 
Internal Medicine | AUTOANTIBODIES | ADULT PATIENTS | IN-VITRO | AMG-531 | MEGAKARYOCYTES | CHRONIC ITP | PLATELET DESTRUCTION | SPLENECTOMY | UMCG Approved | THROMBOPOIETIN LEVELS | TGF-BETA-1 | MEDICINE, GENERAL & INTERNAL | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Male | Treatment Outcome | Recombinant Fusion Proteins | Thrombopoietin | Receptors, Fc - therapeutic use | Carrier Proteins - adverse effects | Splenectomy | Platelet Count | Receptors, Fc - administration & dosage | Carrier Proteins - administration & dosage | Purpura, Thrombotic Thrombocytopenic - drug therapy | Purpura, Thrombotic Thrombocytopenic - immunology | Adult | Female | Aged | Carrier Proteins - therapeutic use | Purpura, Thrombotic Thrombocytopenic - blood | Chronic Disease - drug therapy | Thrombocytopenic purpura | Drug therapy | Research | Clinical trials | Blood diseases | Medical treatment | Chronic illnesses
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
by Kuter, David J and Rummel, Mathias and Boccia, Ralph and Macik, B. Gail and Pabinger, Ingrid and Selleslag, Dominik and Rodeghiero, Francesco and Chong, Beng H and Wang, Xuena and Berger, Dietmar P
The New England Journal of Medicine, ISSN 0028-4793, 11/2010, Volume 363, Issue 20, pp. 1889 - 1899
The platelet-stimulating agent romiplostim was compared with standard interventions for chronic immune thrombocytopenic purpura. Patients given romiplostim had... 
MORTALITY | CONTROLLED-TRIAL | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | EFFICACY | ITP | PURPURA | DOUBLE-BLIND | SPLENECTOMY | COMPLICATIONS | TERM | Glucocorticoids - therapeutic use | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Thrombopoietin - therapeutic use | Thrombopoietin - administration & dosage | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Receptors, Fc - therapeutic use | Splenectomy | Young Adult | Injections, Subcutaneous | Treatment Failure | Aged, 80 and over | Adult | Female | Recombinant Fusion Proteins - administration & dosage | Purpura, Thrombocytopenic, Idiopathic - surgery | Platelet Count | Thrombopoietin - adverse effects | Receptors, Fc - administration & dosage | Adolescent | Intention to Treat Analysis | Quality of Life | Aged | Thrombocytopenic purpura | Medical care | Blood platelets | Drug therapy | Analysis | Quality management | Autoimmune diseases | Medical research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study
by Newland, Adrian and Godeau, Bertrand and Priego, Victor and Viallard, Jean‐Francois and López Fernández, María F and Orejudos, Amelia and Eisen, Melissa
British Journal of Haematology, ISSN 0007-1048, 01/2016, Volume 172, Issue 2, pp. 262 - 273
Summary In anecdotal reports, some patients with immune thrombocytopenia (ITP) maintained platelet counts after discontinuing romiplostim. Here, we examined... 
thrombopoietin receptor agonist | romiplostim | platelet response | immune thrombocytopenia | remission | Romiplostim | Remission | Thrombopoietin receptor agonist | Immune thrombocytopenia | Platelet response | PURPURA ITP | EFFICACY | ADULTS | THROMBOPOIETIN-RECEPTOR AGONISTS | HIGH-DOSE DEXAMETHASONE | THERAPY | RITUXIMAB | 2ND-LINE TREATMENT | RETROSPECTIVE ANALYSIS | HEMATOLOGY | LONG-TERM TREATMENT | Prospective Studies | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Thrombopoietin - therapeutic use | Thrombopoietin - administration & dosage | Receptors, Fc - therapeutic use | Thrombocytopenia - drug therapy | Adult | Female | Blood Platelets - drug effects | Autoimmune Diseases - drug therapy | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Treatment Outcome | Remission Induction | Thrombocytopenia - blood | Autoimmune Diseases - blood | Receptors, Thrombopoietin - agonists | Platelet Count | Thrombopoietin - adverse effects | Receptors, Fc - administration & dosage | Thrombocytopenia | Immune response
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP
by Bussel, James B and Kuter, David J and Pullarkat, Vinod and Lyons, Roger M and Guo, Matthew and Nichol, Janet L
Blood, ISSN 0006-4971, 03/2009, Volume 113, Issue 10, pp. 2161 - 2171
Chronic immune thrombocytopenic purpura (ITP) is characterized by low platelet counts and mucocutaneous bleeding. In previous studies romiplostim (AMG531), a... 
AUTOIMMUNE THROMBOCYTOPENIA | ADULT PATIENTS | INTRAVENOUS GAMMA-GLOBULIN | IN-VITRO | PURPURA | AMG-531 | BONE-MARROW | SPLENECTOMY | PLATELET PRODUCTION | HEMATOLOGY | THROMBOPOIETIN LEVELS | Humans | Middle Aged | Male | Recombinant Fusion Proteins | Thrombopoietin | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Carrier Proteins - adverse effects | Platelet Count | Receptors, Fc - administration & dosage | Carrier Proteins - administration & dosage | Female | Blood Platelets - drug effects | Thrombopoiesis - drug effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights